Flutamide 250mg tablets

240mg

Darolutamide 300mg tablets

300mg

Enzalutamide 40mg tablets

40mg

Apalutamide 60mg tablets

60mg

Enzalutamide 40mg capsules

Capsule

40mg

Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial.

Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Loading prescribing data...

Guidelines from the National Institute for Health and Care Excellence

NICE clinical guidance(1)

Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)

TA316

Technology appraisal

Updated Jul 2014

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & safety information

Official UK regulator monitoring and safety alerts

MHRA drug safety updates

UK regulator alerts and supply notices

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).

Codes for healthcare professionals and prescribing systems

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

42036211000001101

dm+d ID

42036211000001101

VTM (Virtual Therapeutic Moiety)

776015007

VMP (Virtual Medicinal Product)

42036211000001101

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

L02BB01

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Academic studies and reviews for this medicine's active substance

Showing the 50 most relevant studies.

Reviews & meta-analyses: 4 · Randomised trials: 8 · 1986–2026

Sort

P. Moghetti, F. Tosi, A. Tosti, et al.

The Journal of clinical endocrinology and metabolism, 2000

Randomised trial

Cited by 255

Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer.

R. Madan, Marijo Bilusic, M. Stein, et al.

The oncologist, 2023

Randomised trial

Cited by 12

Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial.

Demogeot N, Sargos P, Salleron J, et al.

2025

Randomised trial

Open access

Cited by 1

Prostatic Neoplasms
Flutamide
Androgen Antagonists

Background and objectiveFew studies have compared short-term androgen deprivation (STADT) combined with high-dose radiotherapy (STADT-RT) versus high-dose radiotherapy (RT) alone in localized prostate cancer.MethodsThe GETUG 14 study randomized 376 patients to RT (n = 191) or STADT-RT (n = 179). The RT dose was 80 Gy in both arms. STADT consisted of monthly triptorelin and daily flutamide for a total duration of 4 mo, starting 2 mo before RT. Disease-free survival (DFS) was the primary endpoint. Secondary endpoints were overall survival (OS), biochemical failure (BF), metastasis failure (MF), toxicity, and quality of life.Key findings and limitationsAmong the 370 patients in the modified intention-to-treat population, 241 (65%) had intermediate-risk and 107 (28%) high-risk prostate cancer. At median follow-up among surviving patients of 84 mo (interquartile range 62-99 mo), the 5-yr DFS rate was 76% in RT arm versus 84% in STADT-RT arm (hazard ratio [HR] 0.64, 95% confidence interval [CI] 0.43-0.94]). ADT addition decreased BF (HR 0.45, 95% CI 0.28-0.72) and MF (HR 0.5, 95% CI 0.23-1.11) but not OS (HR 1.22, 95% CI 0.65-2.29). There were no significant differences for RT versus STADT-RT in the incidence rates for grade ≥2 toxicity in terms of acute gastrointestinal (GI) toxicity (26%, 95% CI 20-32 vs 26%, 95% CI 20-33), acute genitourinary (GU) toxicity (39%, 95% CI 32-46% vs 42%, 95% CI 35-50%), late GI toxicity (21%, 95% CI 16-28% vs 23%, 95% CI 18-30%), or late GU toxicity (30%, 95% CI 24-38% vs 27%, 95% CI 21-34%).Conclusions and clinical implicationsSTADT is a well-tolerated and effective strategy that can enhance oncological outcomes when combined with high-dose RT, particularly for patients with intermediate- or high-risk prostate cancer.

Abstract licence: CC BY

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

E. Crawford, M. Eisenberger, D. Mcleod, et al.

The New England journal of medicine, 1989

Cited by 1,441

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

Kenneth Blank

The New England journal of medicine, 1998

Cited by 867

Disruption of androgen-regulated male reproductive development by di(n-butyl) phthalate during late gestation in rats is different from flutamide.

E. Mylchreest, M. Sar, R. Cattley, et al.

Toxicology and applied pharmacology, 1999

Cited by 450

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.

H. Scher, W. Kelly

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993

Cited by 398

Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.

Christine A. Eagleson, M. B. Gingrich, C. Pastor, et al.

The Journal of clinical endocrinology and metabolism, 2000

Cited by 378

Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome.

W. Kelly, H. Scher

The Journal of urology, 1993

Cited by 351

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center.

L. Denis, Carnelro de Moura Jl, Aldo V. Bono, et al.

Urology, 1993

Cited by 260

Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

None known

Half-life

6 hours

Mechanism

Flutamide is a nonsteroidal antiandrogen that blocks the action of both endogeno…

Food interactions

1 warning

Human targets

3 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

Rapidly and completely absorbed.

Half-life

6 hours

The plasma half-life for the alpha-hydroxylated metabolite of flutamide (an active metabolite) is approximately 6 hours.

Protein binding

94-96%

Metabolism

2.5%

Flutamide is rapidly and extensively metabolized, with flutamide comprising only 2.5% of plasma radioactivity 1 hour after administration.

Elimination

4.2%

Flutamide and its metabolites are excreted mainly in the urine with only 4.2% of a single dose excreted in the feces over 72 hours.

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

An antiandrogen with about the same potency as cyproterone in rodent and canine species.

Properties:

solid

Avg. mass: 276.21 Da

View FDA drug label

DrugBank indication

For the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate

Also known as(65)

4'-nitro-3'-trifluoromethylisobutyranilide

Flutamid

Flutamida

Flutamide

Flutamidum

FTA

NFBA

Niftolid

Molecular properties(19)

Drug interactions(1215)

Known interactions with other medicines. Always consult a healthcare professional.

Deferasirox

Moderate

DB01609

The serum concentration of Flutamide can be increased when it is combined with Deferasirox.

Peginterferon alfa-2b

Moderate

DB00022

The serum concentration of Flutamide can be increased when it is combined with Peginterferon alfa-2b.

Leflunomide

Moderate

DB01097

The serum concentration of Flutamide can be decreased when it is combined with Leflunomide.

Teriflunomide

Moderate

DB08880

The serum concentration of Flutamide can be decreased when it is combined with Teriflunomide.

Prilocaine

Moderate

DB00750

The risk or severity of methemoglobinemia can be increased when Flutamide is combined with Prilocaine.

Abiraterone

Moderate

DB05812

The serum concentration of Flutamide can be increased when it is combined with Abiraterone.

Cyproterone acetate

Moderate

DB04839

The metabolism of Flutamide can be increased when combined with Cyproterone acetate.

Dapsone

Moderate

DB00250

The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Flutamide.

Choline C 11

Moderate

DB09277

Flutamide may decrease effectiveness of Choline C 11 as a diagnostic agent.

Capromab pendetide

Moderate

DB00089

Flutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent.

Albendazole

Moderate

DB00518

The metabolism of Flutamide can be increased when combined with Albendazole.

Rifampin

Moderate

DB01045

The metabolism of Flutamide can be increased when combined with Rifampicin.

Primidone

Moderate

DB00794

The metabolism of Flutamide can be increased when combined with Primidone.

Caffeine

Moderate

DB00201

The metabolism of Flutamide can be decreased when combined with Caffeine.

Moxifloxacin

Moderate

DB00218

The metabolism of Flutamide can be decreased when combined with Moxifloxacin.

Mexiletine

Moderate

DB00379

The metabolism of Flutamide can be decreased when combined with Mexiletine.

Alosetron

Moderate

DB00969

The metabolism of Flutamide can be decreased when combined with Alosetron.

Gatifloxacin

Moderate

DB01044

The metabolism of Flutamide can be decreased when combined with Gatifloxacin.

Simeprevir

Moderate

DB06290

The metabolism of Flutamide can be decreased when combined with Simeprevir.

Lobeglitazone

Moderate

DB09198

The metabolism of Flutamide can be decreased when combined with Lobeglitazone.

Pazufloxacin

Moderate

DB11774

The metabolism of Flutamide can be decreased when combined with Pazufloxacin.

Imipramine

Moderate

DB00458

The metabolism of Flutamide can be decreased when combined with Imipramine.

Osilodrostat

Moderate

DB11837

The metabolism of Flutamide can be decreased when combined with Osilodrostat.

Osimertinib

Moderate

DB09330

The serum concentration of Flutamide can be decreased when it is combined with Osimertinib.

Vemurafenib

Moderate

DB08881

The serum concentration of Flutamide can be increased when it is combined with Vemurafenib.

Pitolisant

Moderate

DB11642

The serum concentration of Flutamide can be decreased when it is combined with Pitolisant.

Icosapent

Moderate

DB00159

Icosapent may decrease the excretion rate of Flutamide which could result in a higher serum level.

Cefotiam

Moderate

DB00229

Cefotiam may decrease the excretion rate of Flutamide which could result in a higher serum level.

Mesalazine

Moderate

DB00244

Mesalazine may decrease the excretion rate of Flutamide which could result in a higher serum level.

Cefmenoxime

Moderate

DB00267

Cefmenoxime may decrease the excretion rate of Flutamide which could result in a higher serum level.

Cefmetazole

Moderate

DB00274

Cefmetazole may decrease the excretion rate of Flutamide which could result in a higher serum level.

Pamidronic acid

Moderate

DB00282

Pamidronic acid may decrease the excretion rate of Flutamide which could result in a higher serum level.

Tenofovir disoproxil

Moderate

DB00300

Tenofovir disoproxil may decrease the excretion rate of Flutamide which could result in a higher serum level.

Indomethacin

Moderate

DB00328

Indomethacin may decrease the excretion rate of Flutamide which could result in a higher serum level.

Cidofovir

Moderate

DB00369

Cidofovir may decrease the excretion rate of Flutamide which could result in a higher serum level.

Cefpiramide

Moderate

DB00430

Cefpiramide may decrease the excretion rate of Flutamide which could result in a higher serum level.

Ceftazidime

Moderate

DB00438

Ceftazidime may decrease the excretion rate of Flutamide which could result in a higher serum level.

Loracarbef

Moderate

DB00447

Loracarbef may decrease the excretion rate of Flutamide which could result in a higher serum level.

Cefalotin

Moderate

DB00456

Cefalotin may decrease the excretion rate of Flutamide which could result in a higher serum level.

Ketorolac

Moderate

DB00465

Ketorolac may decrease the excretion rate of Flutamide which could result in a higher serum level.

Tenoxicam

Moderate

DB00469

Tenoxicam may decrease the excretion rate of Flutamide which could result in a higher serum level.

Cefotaxime

Moderate

DB00493

Cefotaxime may decrease the excretion rate of Flutamide which could result in a higher serum level.

Tolmetin

Moderate

DB00500

Tolmetin may decrease the excretion rate of Flutamide which could result in a higher serum level.

Foscarnet

Moderate

DB00529

Foscarnet may decrease the excretion rate of Flutamide which could result in a higher serum level.

Piroxicam

Moderate

DB00554

Piroxicam may decrease the excretion rate of Flutamide which could result in a higher serum level.

Methotrexate

Moderate

DB00563

Methotrexate may decrease the excretion rate of Flutamide which could result in a higher serum level.

Cephalexin

Moderate

DB00567

Cephalexin may decrease the excretion rate of Flutamide which could result in a higher serum level.

Fenoprofen

Moderate

DB00573

Fenoprofen may decrease the excretion rate of Flutamide which could result in a higher serum level.

Valaciclovir

Moderate

DB00577

Valaciclovir may decrease the excretion rate of Flutamide which could result in a higher serum level.

Valdecoxib

Moderate

DB00580

Valdecoxib may decrease the excretion rate of Flutamide which could result in a higher serum level.